Drugs / CVL-936
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04232878 Comparator | Dec 2019 → Mar 2020 | substance-related disorder | Cerevel Therapeutics, LLC | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-01-30 | AbbVie | Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder abbvie.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVL-936 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04232878 ↗ |
| Route | Oral | “single ascending oral doses” NCT04232878 ↗ |